This study assessed blood pressure (BP) reductions and response rates following addition of nebivolol to ongoing antihypertensive therapy in patients with uncontrolled stage I-II hypertension despite antihypertensive treatment. Patients with an average sitting diastolic BP (SiDBP) X90 and p109 mm Hg while taking an antihypertensive regimen were included in this double-blind, placebo-controlled, parallel-group study. The primary efficacy end point was reduction from baseline to week 12 in mean trough SiDBP. In total, 669 patients were randomized to once-daily nebivolol 5, 10 or 20 mg or placebo. Addition of nebivolol 5, 10 and 20 mg significantly reduced BP; placebo-subtracted least squares mean reductions in trough SiDBP were À3.3, À3.5 and À4.6 mm Hg, respectively (Po0.001) and À5.7, À3.7 and À6.2 mm Hg in trough sitting systolic BP (SiSBP), respectively (Pp0.015). Adding nebivolol 5-20 mg resulted in significantly more responders (SiDBP o90 or X10 mm Hg reduction; range: 53.0-65.1 vs 41.3% with placebo; Pp0.028) and significantly better control rates (SiSBP/ SiDBP o140/90 mm Hg; range: 41.3-52.7 vs 29.3% with placebo; Pp0.029). Nebivolol was well tolerated; the incidence of adverse events with nebivolol was similar to that with placebo (40.2 vs 38.9%, respectively; P ¼ 0.763). Addition of once-daily nebivolol to ongoing antihypertensive therapy provided significant additional BP reductions and better response rates in patients with uncontrolled hypertension and was well tolerated.
Introduction
Hypertension has been estimated to affect more than a quarter of the world's adult population. 1 In the majority of patients treated with antihypertensive monotherapy, blood pressure (BP) is not controlled to the recommended target (140/90 mm Hg). [2] [3] [4] Therefore, many hypertensive patients require more than one antihypertensive agent for adequate BP control. 3, 5 As hypertension pathophysiology is multifactorial, combination regimens that utilize different BP-lowering mechanisms and associated compensatory responses may be useful in achieving BP goals. 5 b-Blockers are well-established antihypertensive treatments.
3 b-Blockers are thought to work by lowering heart rate (HR) and sympathetic tone and by inhibiting renin release. [6] [7] [8] Over time, this class has evolved to include agents that are selective for the b 1 -adrenoreceptor and that are vasodilatory. [6] [7] [8] Consequently, currently available b-blockers represent a highly heterogeneous class, differentiated by their pharmacologic effects on b 1 -specificity, peripheral vascular resistance, cardiac output, metabolic profile and overall tolerability. [6] [7] [8] Nebivolol is a selective b 1 -adrenoreceptor blocker 9 that possesses vasodilatory properties. [10] [11] [12] [13] Nebivolol possesses a distinct hemodynamic profile, including reduced peripheral vascular resistance and neutral impact on cardiac output. 6, 14, 15 Nebivolol also provided significant dose-dependent BP reductions in clinical trials in hypertensive patients and was safe and well tolerated. 6, 14, [16] [17] [18] [19] The objective of this study was to assess the BPlowering efficacy and safety of once-daily nebivolol added to ongoing antihypertensive therapy in patients with uncontrolled stage I-II hypertension.
Materials and methods

Study population
Men and women aged 18 years and older with stage I-II hypertension that was inadequately controlled by antihypertensive medication (clinic sitting diastolic BP (SiDBP) X90 and p109 mm Hg measured at screening and baseline) were eligible. Patients had to be on a stable regimen of antihypertensive medications consisting of at least one and no more than two of an angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blocker (ARB) or diuretic. Concomitant use of calcium channel blockers was excluded under the study design protocol.
Exclusion criteria were body mass index (BMI) 435 kg m À2 , malignant hypertension, bradycardia (o50 beats per minute (b.p.m.) at rest in the supine position), respiratory disorders, chronic atrial fibrillation or recurrent tachyarrhythmia, uncontrolled type II diabetes mellitus (haemoglobin A 1c 410% at screening), clinically significant hepatic or renal dysfunction, history of myocardial infarction or cerebrovascular disease in the last 6 months, heart failure requiring treatment, significant valvular heart disease, severe peripheral vascular disease, intolerance to b-blockers or previous exposure to nebivolol for the treatment of hypertension.
All patients gave written informed consent before undergoing any examination or study procedure.
Study design
This was a 12-week, randomized, double-blind, placebo-controlled, parallel-group study conducted at 96 centres in the United States. The study protocol was approved by a central institutional review board and the research was performed in accordance with both Good Clinical Practice guidelines and the Declaration of Helsinki Principles.
Patients underwent a screening assessment including a complete medical history, physical examination, clinic BP and HR measurement, laboratory tests (blood haematology and chemistry, and urinalysis), genomic testing and 12-lead electrocardiography. Patients taking b-blockers at screening underwent a 14 ± 3-day washout before baseline.
At baseline (day 1), demographic and baseline clinical characteristics, including clinic BP and HR measurement, 24-h ambulatory BP monitoring (ABPM) and 12-lead electrocardiogram (ECG) were recorded, and eligible patients were randomized to receive double-blind treatment of concomitant nebivolol 5, 10 or 20 mg or placebo for 12 weeks, once daily in the morning. Patients returned to the study unit for assessments on days 14, 42 and 84 (study end) of the double-blind treatment period, at which time BP and HR were measured, compliance with study medication was monitored and use of concomitant medications was recorded. The 24-h ABPM, 12-lead ECG and laboratory assessments were repeated at the end of the study (day 84).
Concomitant therapy with oral and ophthalmic bblockers, calcium channel blockers, a 1 -receptor blockers and long-acting oral nitrates was prohibited for the duration of the study period.
End points and objectives
The primary efficacy end point was the change from baseline to day 84 in mean clinic SiDBP at trough (24±3 h after previous morning's dose). Secondary efficacy end points included change from baseline to day 84 in mean trough sitting systolic BP (SiSBP), mean SiDBP and SiSBP at peak (2-3 h after dosing), mean peak and trough supine and standing DBP and SBP, and mean 24-h DBP and SBP as measured by ABPM and the responder rate of treatment groups, defined as the proportion of patients with an SiDBP of o90 mm Hg at the end of the study or an absolute reduction of X10 mm Hg in SiDBP from baseline. Additional objectives were to assess the safety and tolerability of nebivolol.
Efficacy and safety assessments BP was measured using a calibrated standard sphygmomanometer and appropriately sized cuff. Measurements were taken at trough and peak drug concentration in the supine, sitting and standing positions. Three separate measurements were taken 2 min apart in the same arm in supine, sitting and standing positions-after the patient had been at rest in the supine position for at least 5 min, then after sitting for 1 min and, finally, after standing for 1 min. The average of the three readings in each position was used for analysis. Trough BP and HR measurements were taken at screening and randomization, and on days 14, 42 and 84 of the treatment period; peak BP and HR measurements were taken at randomization, and on days 42 and 84 of the treatment period.
Non-invasive ABPM was carried out using a device calibrated to within 5 mm Hg of the mean of three DBP measurements taken using a standard sphygmomanometer, and validated independently by the American Association for the Advancement of Medical Instrumentation. During the monitoring period, patients recorded activity information, such as bedtime, time of awakening and arising. The terms 'awake' and 'sleep' BP refer to the averages of all the measurements taken during periods of wakefulness (time of awakening to 1 min before going to bed) and sleep (time of going to bed through to 1 min before awakening), respectively, according to the logs. At baseline and on day 84, 24-h ambulatory BP was measured every 20 min during daytime hours (awake; 0600-2200), and every 30 min during nighttime hours (asleep; 2200-0600). The ABPM recording was accepted if it included at least 24 h of recording following administration of a dose, had at least 60 valid readings (80% acceptance rate) and had no more than 2 nonconsecutive hours of missing data.
Safety was assessed by monitoring adverse events (AEs), physical examination, body weight, ECG and laboratory evaluation, including chemistry panel, haematologic profile and urinalysis.
Statistical methods
The intent-to-treat (ITT) population, which included all randomized patients who took at least one dose of study drug, was the primary population for efficacy and safety analyses. Efficacy analysis was also carried out on the per protocol population, which included all ITT patients who had no major protocol violations. Missing values were imputed using the last-observation-carried-forward method. All statistical tests were two sided at the 5% level of significance.
On the basis of standard deviation of 7.2 mm Hg for SiDBP, it was estimated that, with 150 patients per treatment group, the study would have 80% power at 0.0167 significance level (two tailed) to detect a 3 mm Hg difference between the placebo and nebivolol dose groups. Thus, 600 patients were estimated for randomization.
For demographic and baseline characteristics, continuous variables were compared among treatment groups using an analysis of variance (ANOVA) model and categorical variables were compared using the w 2 -test. Changes in BP from baseline to the end of the study were analysed using an analysis of covariance (ANCOVA) model, with study treatment, race (African American, non-African American), age (o65 years, X65 years), gender, diabetes status (yes, no), predicted metabolism of nebivolol (based on CYP2D6 genotype) and use of an ACE inhibitor, ARB and diuretic as factors in the model, and baseline measurement as a covariate. For pairwise comparisons between each of the three nebivolol treatment groups and placebo, the P-values were adjusted using Hochberg's hierarchical step-up procedure. Pairwise comparisons with 95% confidence intervals were also performed for each nebivolol dose group and placebo.
The proportion of patients defined as responders (SiDBP o90 or X10 mm Hg reduction from baseline) between each nebivolol treatment group and placebo were analysed using a logistic regression model with responder as the response variable, and baseline DBP and dichotomous variables as covariates. The percentage of patients achieving BP control (SiDBP o90 mm Hg and SiSBP o140 mm Hg) at the end of the study with each nebivolol dose was analysed post hoc and compared with placebo using Pearson's w 2 -test. For safety analyses, the w 2 -test was used to determine the overall effect of treatment on the distribution of AEs, and the Mantel-Haenszel test was used to determine the dose-trend effect. Laboratory parameters were compared statistically among treatment groups using ANOVA or ANCOVA (baseline as covariate).
Results
Patient disposition and baseline characteristics
A total of 1171 patients were screened and 502 were ineligible; therefore, 669 patients were randomized to receive either placebo or nebivolol and received at least one dose of study medication (the ITT population; Figure 1 ). A total of 598 patients (89.4%) completed the study: 146 patients (87.4%) in the placebo group and 452 (90.0%) in the combined nebivolol groups. The most common reasons for discontinuation were withdrawal of consent (4.0%), AEs (3.7%) and loss to follow-up (1.5%).
There were no statistically significant differences among treatment groups at baseline with respect to use of background antihypertensive therapy (Table 1) . Patients were on established background antihypertensive therapy for periods ranging from 30 days to more than 3 years before screening; 486 patients (72.6%) were taking one medication and 176 patients (26.3%) were taking two medications. The majority of patients taking ACE inhibitors, diuretics and ARBs were prescribed doses that were within the recommended range. Although these doses, including the doses of combinations thereof (ACE inhibitor/ARB, ACE inhibitor/diuretic, ARB/ diuretic), were less than the maximal indicated dose, they represented common clinical practice patterns. Seven patients (1.0%) not taking the appropriate background antihypertensive therapy were randomized due to misclassification of the medications being taken and were, therefore, excluded from per protocol population analyses.
Demographic and baseline characteristics of randomized patients were comparable across treatment groups (Table 2) . Patients comprised mainly middleaged (mean ¼ 53 years), overweight (mean BMIE30) hypertensive patients, 55% of whom were men; 55% were Caucasian, 29% African American, 15% Hispanic and 1% Asian; and 14.1% were diabetic.
Effect of nebivolol addition on blood pressure Addition of nebivolol to background antihypertensive therapy led to significant additional BP reductions compared with placebo (Table 3; Figure 2 ). Nebivolol 5, 10 and 20 mg significantly lowered trough SiDBP (placebo-subtracted least squares (LS) mean change from baseline) by À3.3, À3.5 and À4.6 mm Hg, respectively (Po0.001 for all nebivolol doses). The corresponding values for SiSBP were À5.7, À3.7 and À6.2 mm Hg, respectively (Po0.001 for nebivolol 5 and 20 mg; P ¼ 0.015 for nebivolol 10 mg). Similar BP-lowering effects were observed in the per protocol population (data not shown).
The significant incremental BP reductions in the nebivolol treatment groups, compared with placebo, were apparent by week 2 (first assessment following randomization); BP reductions were sustained throughout the remainder of the 12-week treatment period. Reductions in trough BP in the standing and supine positions were comparable to sitting BP reductions for all nebivolol doses. All doses of nebivolol also significantly reduced peak SiDBP and SiSBP at week 12, compared with placebo (Po0.001 for both peak SiDBP and SiSBP); placebo-subtracted LS mean reductions from baseline in peak SiDBP were À3.2, À4.0 and À4.3 mm Hg for nebivolol 5, 10 and 20 mg, respectively. Similarly, for peak SiSBP, placebo-subtracted LS mean reductions from baseline were À5.7, À5.6 and À5.9 mm Hg for nebivolol 5, 10 and 20 mg, respectively. Reductions from baseline to week 12 in peak BP with nebivolol in both supine and standing positions were consistent with those for SiDBP and SiSBP (data not shown). Placebo-subtracted trough-to-peak ratios of the change in SiDBP from baseline to week 12 were 0.88 or above across nebivolol dose groups (responders and non-responders combined), demonstrating that once-daily dosing is appropriate.
Addition of nebivolol 5-20 mg to patients' ongoing antihypertensive therapy was significantly more effective in further lowering mean 24-h ambulatory BP than placebo. The placebo-subtracted LS mean differences from baseline to day 84 in 24-h ambulatory DBP were À5.0, À4.8 and À5.4 mm Hg for the nebivolol 5-, 10-and 20-mg groups, respectively (Po0.001; Table 4 ). Nebivolol treatment also produced significant reductions in ambulatory DBP during both awake and asleep periods (Pp0.03 for both). In addition, nebivololtreated patients exhibited significant reductions in mean 24-h ambulatory SBP vs placebo (placebosubtracted LS mean, range: À3.4 to À4.8 mm Hg; Pp0.005).
A post hoc analysis examined the effects of the addition of nebivolol to each different background therapy. This analysis showed that the addition of nebivolol to existing background monotherapy or background multidrug therapy produced further reductions in BP. When added to either an ACE inhibitor, ARB or diuretic, nebivolol 5-20 mg was associated with significant additional reductions from baseline in peak sitting BP of À14.0/À12.9, À13.8/À12.1 and À14.2/À13.3 mm Hg, respectively, compared with À8.6/À8.5 for patients treated with placebo plus background therapy of one agent (Po0.001 for nebivolol plus background monotherapy vs placebo). Moreover, the addition of nebivolol 5-20 mg to background multidrug combinations was associated with further reductions from baseline in peak sitting BP. When added to combination therapy with an ACE/diuretic, nebivolol further reduced peak sitting BP by À12.0/À11.4 mm Hg; when added to combination therapy with an ARB/diuretic, the additional peak BP reductions were À14.8/ À13.1 mm Hg. These compared with À7.6/ À10.2 mm Hg for patients treated with placebo plus background multidrug therapy.
Effect of nebivolol addition on responder and control rates After 12 weeks of treatment, the proportion of patients achieving a successful treatment response (reduction in trough SiDBP to o90 mm Hg or a reduction of X10 mm Hg from baseline) was significantly higher with nebivolol 5 mg (53.0%; P ¼ 0.028), 10 mg (60.1%; P ¼ 0.001) and 20 mg (65.1%; Po0.001) than placebo (41.3%; Figure 2c ). In addition, a significantly higher percentage of patients achieved BP control (BP o140/90 mm Hg) in nebivolol dose groups; 43.2, 41.3 and 52.7% with Effect of nebivolol addition on heart rate Addition of nebivolol to background antihypertensive therapy resulted in statistically significant reductions from baseline to the end of the study in mean trough sitting HR compared with placebo. The placebo-subtracted LS mean reductions were À4.3, À4.6 and À7.6 b.p.m. for nebivolol 5, 10 and 20 mg, respectively (Po0.001 for all doses). Similar trends were observed for peak sitting HR, and for peak and trough supine and standing HR (data not shown).
Safety and tolerability
The overall incidence of treatment-emergent AEs was comparable among the placebo (38.9%) and combined nebivolol (40.2%) groups (P ¼ 0.763).
There was no dose-dependent increase in the incidence of AEs in the nebivolol groups; 40.5, 41.1 and 39.2% in the nebivolol 5-, 10-and 20-mg groups, respectively. For nebivolol vs placebo, the most frequently reported AEs were headache (5.0 vs 2.4%), fatigue (3.6 vs 2.4%), urinary tract infection (3.2 vs 3.6%), dizziness (2.4 vs 1.8%) and nasopharyngitis (2.2 vs 1.2%; Table 5 ). No AEs occurred at a significantly higher rate in nebivolol-treated vs placebo-treated patients. In addition, the incidence of other AEs of interest was low in the combined nebivolol groups vs placebo, respectively, bradycardia (0.8 vs 0.0%), orthostatic hypotension (0.0% for all patients), decreased libido (0.4 vs 0.0%) or unspecified sexual dysfunction (0.0 vs 0.6%) and depression (0.2 vs 0.0%). AEs of severe intensity were reported in 2.4% of placebo-treated patients and 2.2% of patients in the combined nebivolol groups, and were not related to nebivolol dose (nebivolol 5 mg, 3.0%; 10 mg, 1.2%; 20 mg, 2.4%). There was one death during the study. A 75-year-old woman died due to cardiac arrest in the hospital following diagnosis of myocardial infarction. The event occurred 1 day after starting nebivolol 5 mg, and was judged by the investigators to be remotely related to study drug. Seven other patients (three in the placebo group and four in the nebivolol group) reported 11 serious AEs, none of which were considered to be related to study drug.
A total of 25 patients withdrew from the study due to AEs, including 4 (2.4%) in the placebo group and 21 (4.2%) of the patients treated with nebivolol. No dose relationship was observed for AEs leading to withdrawal (5.4% in the nebivolol 5-mg group, 3.0% in the 10-mg group and 4.2% in the 20-mg group). The most common AEs leading to study withdrawal were fatigue (3.6%, all doses of nebivolol combined) and headache (5%, all doses of nebivolol combined).
Changes in chemistry and haematology laboratory values from baseline to day 84, including measures of renal and hepatic function and major electrolytes, were generally small and not statistically significant. No significant change from baseline was observed with nebivolol treatment in most laboratory parameters associated with cardiovascular risk, including low-density lipoprotein cholesterol (LDL-C), triglycerides or blood glucose (Table 5 ). However, small but statistically significant reductions in Figure 2 Blood pressure and response rates at week 12. Placebosubtracted least mean reduction (95% confidence intervals) in trough sitting diastolic blood pressure (a) and trough sitting systolic blood pressure (b) from baseline to the end of the study. (c) Response rates (trough sitting diastolic blood pressure of o90 mm Hg or a reduction from baseline of X10 mm Hg) at the end of the study (week 12). *Po0.001; w P ¼ 0.015;
Nebivolol added to ongoing antihypertensive therapy JM Neutel et al high-density lipoprotein cholesterol (HDL-C) were observed in nebivolol-treated patients, although no relationship to dose was seen (Table 5) .
Discussion
This study has demonstrated that adding once-daily nebivolol 5-20 mg to an established background antihypertensive treatment regimen produced significant additional reductions in BP, maintained over 24 h, in patients with uncontrolled stage I-II hypertension despite antihypertensive treatment. Importantly, addition of nebivolol 5-20 mg also resulted in high response rates (ranging from 53 to 65%, based on DBP criteria) with nearly twice as many patients achieving BP control (41-53%) as with placebo. From an analysis of covariance model with treatment as factor and screening measurement as covariate.
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Non-invasive 24-h ABPM was also used in this study, as it is a better predictor of cardiovascular events than clinic BP in treated hypertensive subjects. 4, 20 The ABPM profiles showed that nebivolol addition provided greater statistically significant decreases in both mean 24-h DBP and SBP than placebo, confirming the findings from the clinic. Interestingly, the ABPM profiles in this study showed BP decreases in the placebo group; however, it is important to note that patients were randomized on the basis of clinic DBP measurements and not ABPM. AMBP profiles in previous studies have shown that BP reductions in placebo-treated patients are largely absent if patients are enrolled on the basis of ABPM. 21 In the clinic environment, patients may exhibit so-called 'white coat hypertension'. Indeed, in this study, baseline ABPM readings were lower in all groups than baseline clinic BP measurements (data not shown). This finding may have impacted the small BP decreases seen in the placebo group as demonstrated by ABPM.
Although previous monotherapy studies of nebivolol have demonstrated a linear dose-response relationship for doses of nebivolol above 5 mg, 14, [22] [23] [24] [25] no clear dose response was observed in this study with the addition of nebivolol to other antihypertensive drugs, particularly with respect to SBP. The SBP results may be influenced by the fact that entry criteria for the study were based on DBP rather than SBP, and the study was powered to show changes in DBP, potentially impacting the significance, magnitude and consistency of the SBP reductions. Overall, the DBP and SBP reductions as well as the response rates observed in this trial are confirmatory of the BP reductions observed in the three registration trials of nebivolol monotherapy vs placebo conducted in over 2000 patients with stage I-II hypertension. 14, 15, 26 Use of antihypertensive therapies with complementary mechanisms of action is advocated for optimal control of BP due to the multifactorial aetiology of hypertension. 5 Perhaps for this reason, combination therapy of b-blockers with ACE inhibitors or ARBs has not always demonstrated additive benefits, as they both target the reninangiotensin system. 27 This may impact clinical practice as b-blockers typically are added on later in the antihypertensive treatment algorithm. The addition of nebivolol, regardless of whether to an ACE inhibitor, ARB or diuretic, was associated with significant additional reductions that may be viewed as evidence for the earlier use of this agent and may be related to the potential mechanism of vasodilation. It would be important to further investigate any differences in the magnitude of BP reductions induced by the combination of nebivolol with each individual therapeutic antihypertensive class. This would enable selection of optimal antihypertensive treatments as add-ons. Further investigation into the effect of adding nebivolol to specific therapies is warranted.
In this study, nebivolol as an add-on treatment was well tolerated, the incidence of AEs being comparable to placebo at all doses. These findings are consistent with the results of previous placebocontrolled monotherapy studies of nebivolol. 14 Furthermore, the incidence of side effects, such as fatigue, bradycardia, decreased libido and sexual dysfunction, was low. Although there were no statistically significant differences in glucose and triglyceride levels between nebivolol and placebotreated groups, small but statistically significant reductions in HDL-C were observed. These reductions appeared to be unrelated to nebivolol dose and may warrant further investigation. No other adverse metabolic effects were observed with nebivolol. The tolerability results from this study support the use of nebivolol as add-on therapy.
Both diuretics and b-blockers have been observed to cause metabolic disturbances, including increases in glucose levels. 28 In this study, no effect on serum glucose levels was observed, correlating with similar findings with respect to effects on glucose metabolism in previous studies of nebivolol. [29] [30] [31] [32] Thus, the data in this study may further support the use of nebivolol as an appropriate add-on therapy. 33 The additional BP lowering provided by nebivolol as add-on therapy has the potential to reduce the risks of uncontrolled hypertension, without compromising tolerability.
In conclusion, once-daily nebivolol, when added to background antihypertensive therapy, provided antihypertensive efficacy with a low incidence of side effects, and increased the BP responder rate across a hypertensive population. Thus, add-on therapy with nebivolol is an effective and welltolerated treatment option for patients with uncontrolled hypertension, despite receiving background antihypertensive therapy.
What is known about this topic?
K Use of combination antihypertensive therapies is advocated for optimal control of BP due to the multifactorial aetiology of hypertension.
5
K Combination therapy of b-blockers with ACE inhibitors or ARBs has not always demonstrated additive benefits, perhaps because they both target the renin-angiotensin system.
26
K Diuretics and b-blockers have been observed to cause metabolic disturbances, including increases in glucose levels, 27 leading to concern over the metabolic risks of using these agents in combination. 28 What this study adds?
K Once-daily therapy with the b-blocker nebivolol, when added to background antihypertensive therapy, provided antihypertensive efficacy with a favourable tolerability profile, and increased the BP responder rate across a general population US patients. K Nebivolol possesses a distinct pharmacodynamic profile, including its vasodilatory properties. K In this study, no effect on serum glucose levels was observed.
